Azacitidine

• NMDSG-14B2 Recruiting
  2024-511651-17-00 Phase II 4 countries Karolinska University Hospital
• The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting
  2023-510515-19-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• Preemptive treatment with venetoclax plus azacitidine in patients diagnosed with acute myeloid leukemia (AML) with persistence or reappearan… Ended
  2024-510648-29-00 Phase II/III 1 country Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodispla…
• A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone … Ended
  2024-510991-19-00 Phase II 2 countries Oncoverity Inc.
• FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatme… Ended
  2022-501372-25-00 Phase II 1 country French Innovative Leukemia Organization
• Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran… Ended
  2024-514876-41-00 Phase I/II 1 country Groupe Francophone Des Myelodysplasies
• Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended
  2024-514878-53-00 Phase II 1 country Groupe Francophone Des Myelodysplasies
• Roll-over study for patients who have completed a prior Novartis sponsored sabatolimab (MBG453) study and are judged by the investigator to … Ended
  2024-515281-14-00 Phase II 6 countries Novartis Pharma AG
• Study of the safety and efficacy of treatment venetoclax + azacitidine and donor lymphocyte infusion in patients with MDS or AML in relapse … Ended
  2024-514877-23-00 Phase I/II 1 country Groupe Francophone Des Myelodysplasies
• A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP… Ended
  2023-506582-58-00 Phase I (Other) 4 countries Janssen - Cilag International
• Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi… Ended
  2023-510432-36-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Study of the Efficacy and Safety of Galinpepimut-S (GPS) for the Treatment of Acute Myeloid Leukemia Compared to Investigator's Choice of … Ended
  2024-516405-23-00 Phase III 5 countries Sellas Life Sciences Group Inc.
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk… Ended
  2023-507153-16-00 Phase III 9 countries AbbVie Deutschland GmbH & Co. KG
• A study of IMGN632 alone or in combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia Ended
  2024-514197-50-00 Phase I/II 4 countries AbbVie Deutschland GmbH & Co. KG
• Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended
  2024-515375-35-00 Phase II 2 countries GWT-Tud GmbH
• OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN A… Ended
  2024-516048-24-00 Phase II 1 country Centre Hospitalier De Versailles
• Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1 Ended
  2024-515352-20-00 Phase II 1 country Groupe Francophone Des Myelodysplasies
• study of the efficacy of treatment with AG-221 in patients with myelodysplastic syndrome and mutation IDH2 Ended
  2024-513858-29-01 Phase II 2 countries Groupe Francophone Des Myelodysplasies
• A Phase 3 study to test the AG-120 in combination with Azacitidine in comparison with the use of Azacitidine alone in patients ≥ 18 Years of… Ended
  2024-514309-73-00 Phase III 5 countries Institut De Recherches Internationales Servier IRIS
• A clinical trial to evaluate the safety and effectiveness of a combination of either AG-12or AG-221 tablets with azacitidine injections in p… Ended
  2024-511722-31-00 Phase I/II 4 countries Celgene Corp.
• A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory A… Halted
  2024-516641-39-00 Phase I (FiH) 4 countries Ab Science
• A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug… Halted
  2024-514588-24-00 Phase I (FiH) 1 country Ellipses Pharma Limited
• An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogen… Ended
  2022-501537-23-00 Phase II 1 country University of Leipzig
• Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) Ended
  2023-510144-20-00 Phase I/II 6 countries Blueprint Medicines Corp.

Showing 25–48 of 66 trials